Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390039 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery
A Phase 3 study, sponsored by Javelin Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT00390039 is a Phase 3 study that has completed, run by Javelin Pharmaceuticals. The registered enrollment target is 256 participants.
The verdict
NCT00390039, a Phase 3 study, has completed, sponsored by Javelin Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
Multiple-center, multiple-dose, randomized, double-blind, six-arm, active- and placebo-controlled study in patients with moderate to severe post-surgical pain from elective orthopedic surgery with safety observed for a total of 30 hours post first dose.
Interventions
- DRUG Placebo
- DRUG Intranasal Morphine
- DRUG IV morphine
- DRUG Intranasal morphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390039
The ClinicalTrials.gov registry entry for NCT00390039 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Javelin Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00390039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390039 about?
NCT00390039 is a clinical study titled "Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery". Multiple-center, multiple-dose, randomized, double-blind, six-arm, active- and placebo-controlled study in patients with moderate to severe post-surgical pain from elective orthopedic surgery with safety observed for a total of 30 hours post first dose.
What is the current status of trial NCT00390039?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2006-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00390039?
The interventions under investigation include: Placebo (DRUG), Intranasal Morphine (DRUG), IV morphine (DRUG), Intranasal morphine (DRUG).
Who is sponsoring clinical trial NCT00390039?
This trial is sponsored by Javelin Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.